TARA
Protara Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protara Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
No other changes.
No other changes.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Largest filed tie
0
filed ties
Annual filing, covered
10-K parsed · Mar 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−4.87%
vs ±21.5% implied · ×0.23
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Protara Therapeutics, Inc.'s 5 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Protara Therapeutics, Inc.'s 5 closest co-movers, none share that code.
Protara Therapeutics, Inc.
2.39
−0.02 · −0.94%
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $17.9M | 10.18% | — |
| BlackRockindex-like | $14.0M | 7.95% | +7.91% |
| Millennium | $11.8M | 6.73% | +9.54% |
| Velan Capital | $10.9M | 6.17% | +0.35% |
| Vanguardindex-like | $8.8M | 4.99% | +8.55% |
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $17.9M | 10.18% | — |
| BlackRockindex-like | $14.0M | 7.95% | +7.91% |
| Millennium | $11.8M | 6.73% | +9.54% |
| Velan Capital | $10.9M | 6.17% | +0.35% |
| Vanguardindex-like | $8.8M | 4.99% | +8.55% |
Bull1
Bear1
Expected move
No implied move.